Phase 2 Ovarian Cancer Trial, Recruiting (NCT07182526)

Phase 2 Ovarian Cancer Trial, Recruiting NCT07182526 Sponsor: Al-Mustansiriyah University Condition: Ovarian Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07182526 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ovarian Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been newly diagnosed and are of reproductive age, between 18 and 40 years old.
People whose ultrasound scan has shown the presence of small cysts on the ovaries (micro polycystic ovaries).
People who have irregular periods, with gaps between periods longer than 35 days.
People who show signs of higher-than-normal male hormone levels, such as acne or excess hair growth (hirsutism).
People whose prolactin hormone levels (PRL) are within the normal range.

Who may not be able to join:

People who have a condition where the adrenal glands do not produce certain enzymes correctly, or who have another hormonal or endocrine condition, including diabetes.
People who have other significant health conditions, such as high blood pressure, heart or blood vessel disease, or hormonal disorders.
People who have been using oral contraceptives, hormonal therapy, or cholesterol-lowering medications.
People who are currently pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 7816871131

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07182526

Sponsor: Al-Mustansiriyah University

Phase: Phase 2

Status: Recruiting

Condition: Ovarian Cancer

Trial contact: 7816871131

More information: https://clinicaltrials.gov/study/NCT07182526

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been newly diagnosed and are of reproductive age, between 18 and 40 years old.
People whose ultrasound scan has shown the presence of small cysts on the ovaries (micro polycystic ovaries).
People who have irregular periods, with gaps between periods longer than 35 days.
People who show signs of higher-than-normal male hormone levels, such as acne or excess hair growth (hirsutism).
People whose prolactin hormone levels (PRL) are within the normal range.

Who may not be able to join:

People who have a condition where the adrenal glands do not produce certain enzymes correctly, or who have another hormonal or endocrine condition, including diabetes.
People who have other significant health conditions, such as high blood pressure, heart or blood vessel disease, or hormonal disorders.
People who have been using oral contraceptives, hormonal therapy, or cholesterol-lowering medications.
People who are currently pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Al-Mustansiriyah University

Registry

ClinicalTrials.gov

Start date

20 September 2025

Est. completion

1 May 2026

Where this trial is recruiting

Iraq

Primary endpoints

Change in Hormonal Profile (LH, FSH, Testosterone) from Baseline; Change in Glycemic Control Markers (Fasting Glucose, Insulin, HOMA-IR) from Baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov